# The Efficacy and Safety of TAF vs Other NAs in Patients With LVL

> **NCT04501224** · NA · UNKNOWN · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 200 (estimated)

## Conditions studied

- Chronic Hepatitis b
- Cirrhosis Due to Hepatitis B

## Interventions

- **DRUG:** Tenofovir alafenamide fumarate
- **DRUG:** Entecavir or Tenofovir disoproxil fumarate

## Key facts

- **NCT ID:** NCT04501224
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-03
- **Primary completion:** 2021-10-31
- **Final completion:** 2024-04-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501224, "The Efficacy and Safety of TAF vs Other NAs in Patients With LVL". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04501224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*